Cancer drug resistance research leads to possible therapeutic target for Alzheimer's disease

May 20, 2004

A protein that allows human cancer to resist multiple anticancer drugs also appears to play a key role in Alzheimer's disease, according to research conducted at Fox Chase Cancer Center. The protein, active in brain tissue, could be a target for new drugs to treat patients with Alzheimer's.

The report will appear in advance online publication the of the prestigious Federation of American Societies for Experimental Biology Journal (www.fasebj.org) on May 20, and will appear in the journal's July issue. The research was conducted in the Fox Chase laboratory of Kenneth D. Tew, Ph.D., D.Sc.

Tew's research has largely concentrated on understanding and circumventing mechanisms of cellular resistance to anticancer drugs and understanding cellular pathways that affect drug response and resistance. The new report concerns the human ABCA2 transporter, one of a large family of ATP-binding proteins that transport a variety of molecules across biological membranes.

ATP (adenosine triphosphate) is present in all living cells and serves as a major energy source for cellular reactions. Related transporter proteins with varying functions (there are over 50 coded for by the human genome) are widely expressed in human tissues according to Tew.

"The overexpression of the ABCA2 protein has been implicated in acquired resistance of tumors to the drug estramustine, which is used to treat prostate cancer patients," explained Tew, senior author of the paper. "This transporter is also expressed at high levels in brain tissue and may be linked with the transport of molecules relevant to the etiology of Alzheimer's disease, including those involved in the formation of amyloid plaques. The association of the transporter with Alzheimer's first emerged from a comparative gene expression pattern analysis that we did."

To analyze small changes in gene expression with little material, his laboratory developed Amplified Differential Gene Expression (ADGE) technology and ADGE microarray ("gene chip" technology for rapid analysis of gene expression) to examine cell lines made to express high levels ABCA2 protein. The microarray analysis revealed alterations in gene clusters related either to transport function or to oxidative stress response. This observation tied in with metabolism of free radicals and of beta-amyloid, a primary component of Alzheimer's disease plaques, consisting of dense deposits of protein and cellular material.

According to Tew, ABCA2 can play a role in cholesterol transport and also in myelination--an "insulation" for nerve cells in mammals and other vertebrates. Because these neurons are longer than other cells, they are more vulnerable to damage. Myelin protects them by sheathing their axons--threadlike extensions of the nerve cells--in alternating layers of protein and fat. A new model of human brain aging (Neurobiology of Aging, January 2003) postulates that mid-life breakdown of myelin could be a possible key to the later development of Alzheimer's disease.

"Imaging studies and examination of brain tissue have shown that the deterioration of myelin triggers the degeneration of complex neural connections," Tew said. "This may be due to genetic factors as well as the brain's own process of increasing cholesterol and iron levels in middle age.

"In samples of brain sections from Alzheimer's patients, the ABCA2 protein shows unusual patterns of expression," Tew added. "That also suggests that this transporter has a possible role in Alzheimer's."

Tew was chairman of pharmacology at Fox Chase until this May. He is now chairman of the Department of Cell and Molecular Pharmacology and Experimental Therapeutics at the Medical University of South Carolina in Charleston.

Tew's co-authors on the new FASEB Journal paper include technical specialist Zhijian J. Chen, postdoctoral fellow Bojana Vulevic, Ph.D., scientific technician Kristina Ile and postdoctoral associates Athena Soulika, Ph.D., and Warren Davis Jr., Ph.D., all of Fox Chase; Peter B. Reiner, Ph.D., Bruce P. Connop, Ph.D., and Parimal Nathwani, Ph.D., of Active Pass Pharmaceuticals Inc., in Vancouver, British Columbia; and John Q. Trojanowski, M.D., Ph.D., of the University of Pennsylvania's Center for Neurodegenerative Disease Research.
-end-
Grants from the National Institutes of Health and a Commonwealth of Pennsylvania appropriation helped support this work.

Fox Chase Cancer Center was founded in 1904 in Philadelphia, Pa., as the nation's first cancer hospital. In 1974, Fox Chase became one of the first institutions designated as a National Cancer Institute Comprehensive Cancer Center. Fox Chase conducts basic, clinical, population and translational research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the Center's web site at www.fccc.edu or call 1-888-FOX CHASE.

Fox Chase Cancer Center

Related Brain Articles from Brightsurf:

Glioblastoma nanomedicine crosses into brain in mice, eradicates recurring brain cancer
A new synthetic protein nanoparticle capable of slipping past the nearly impermeable blood-brain barrier in mice could deliver cancer-killing drugs directly to malignant brain tumors, new research from the University of Michigan shows.

Children with asymptomatic brain bleeds as newborns show normal brain development at age 2
A study by UNC researchers finds that neurodevelopmental scores and gray matter volumes at age two years did not differ between children who had MRI-confirmed asymptomatic subdural hemorrhages when they were neonates, compared to children with no history of subdural hemorrhage.

New model of human brain 'conversations' could inform research on brain disease, cognition
A team of Indiana University neuroscientists has built a new model of human brain networks that sheds light on how the brain functions.

Human brain size gene triggers bigger brain in monkeys
Dresden and Japanese researchers show that a human-specific gene causes a larger neocortex in the common marmoset, a non-human primate.

Unique insight into development of the human brain: Model of the early embryonic brain
Stem cell researchers from the University of Copenhagen have designed a model of an early embryonic brain.

An optical brain-to-brain interface supports information exchange for locomotion control
Chinese researchers established an optical BtBI that supports rapid information transmission for precise locomotion control, thus providing a proof-of-principle demonstration of fast BtBI for real-time behavioral control.

Transplanting human nerve cells into a mouse brain reveals how they wire into brain circuits
A team of researchers led by Pierre Vanderhaeghen and Vincent Bonin (VIB-KU Leuven, Université libre de Bruxelles and NERF) showed how human nerve cells can develop at their own pace, and form highly precise connections with the surrounding mouse brain cells.

Brain scans reveal how the human brain compensates when one hemisphere is removed
Researchers studying six adults who had one of their brain hemispheres removed during childhood to reduce epileptic seizures found that the remaining half of the brain formed unusually strong connections between different functional brain networks, which potentially help the body to function as if the brain were intact.

Alcohol byproduct contributes to brain chemistry changes in specific brain regions
Study of mouse models provides clear implications for new targets to treat alcohol use disorder and fetal alcohol syndrome.

Scientists predict the areas of the brain to stimulate transitions between different brain states
Using a computer model of the brain, Gustavo Deco, director of the Center for Brain and Cognition, and Josephine Cruzat, a member of his team, together with a group of international collaborators, have developed an innovative method published in Proceedings of the National Academy of Sciences on Sept.

Read More: Brain News and Brain Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.